A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY OF ORAL PF-06651600 AND PF-06700841 AS INDUCTION AND CHRONIC THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY OF ORAL PF-06651600 AND PF-06700841 AS INDUCTION AND CHRONIC THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.
Inclusion Criteria:
Exclusion Criteria:
Los Angeles, California 90045, United States
New York, New York 10021, United States
Hilleroed, 3400, Denmark
Budapest, 1125, Hungary
Wroclaw, 54-144, Poland
Bucharest, Sector 1, 010825, Romania
Moscow, 119435, Russia
Rostov-on-Don, 344022, Russia
Samara, 443029, Russia
Yaroslavl, 150062, Russia
Zemun, Belgrade, 11080, Serbia
Ankara, 06100, Turkey (Türkiye)
Kozlu Zonguldak, 67600, Turkey (Türkiye)
Chernivtsi, 58001, Ukraine
Kherson, 73000, Ukraine
Kropyvnytskyi, 25006, Ukraine
Lviv, 79007, Ukraine
Ternopil, 46002, Ukraine